Sector: HealthcareIndustry: Biotechnology

ABVC BioPharma Inc

Current Price

ABVC Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies and medical devices that target significant unmet medical needs, primarily within the U.S. market. With a robust...|

Overview

Market Cap$61.97M

52W High / Low$5 / $0

P/EN/A

PEGN/A

Book Value$0.51

Dividend/ShareN/A

Dividend YieldN/A

EPS$-0.27

Revenue/Share$0.05

OPM-1.47%

NPM0.00%

ROA-17.20%

ROE-47.70%

Gross Profit$797,920

Forward PEN/A

Price to Sales77.66

Price to Book5.46

EV to Sales83.96

EV to EBITDA-1.90

Beta0.24

50D Moving Avg$2.91

200D Moving Avg$2.13

Institutional Holding3.23%

Insider Holding11.37%

Trailing P/EN/A

Qtr EPS GrowthN/A

Qtr Revenue Growth1.04%

Add ratio to table

e.g. Promoter holding

Edit Ratios

Loading price data...

Earnings Estimates

Analyst consensus EPS and Revenue forecasts.

Show growth under values

Years:

Unit:

Metric (B)	FY 2021	FY 2022	FY 2023	FY 2024
EPS Estimate (avg)	$-0.23	$-0.52	$0.00	$0.00
Revenue Estimate (avg)	0	0	0	0
EPS Revision (30d avg)	+0.0%	+0.0%	—	—

Peer Comparison

Showing 5 peers (Same Industry)

S.No.	Name	Symbol	Market Cap	P/E	P/B	Profit Margin	Op. Margin	ROE	Rev. Growth
1.	CytoMed Therapeutics Ltd	GDTC	$22.53M	—	3.92	—	-452.20%	-42.30%	101.00%
2.	Instil Bio Inc	TIL	$73.11M	—	0.65	—	—	-50.60%	—
3.	Rein Therapeutics Inc	RNTX	$38.90M	—	34.83	—	—	-83.30%	—
4.	Citius Pharmaceuticals Inc	CTXR	$23.27M	—	0.41	—	—	-54.70%	—
5.	Nkarta Inc	NKTX	$123.59M	—	0.40	—	—	-26.70%	—

Quarterly Results

Consolidated Figures in Millions / View Standalone.

View:

Show growth under values

Quarters:

Unit:

Quarter (M)	Dec 23	Mar 24	Jun 24	Sep 24	Dec 24	Mar 25	Jun 25	Sep 25
Sales	0	0	0.12	0.39	0	0	0	0.8
Expenses	1.82	2.84	0.98	0.34	0.34	0.69	2.29	1.96
Operating Profit	-2.05	-2.75	-0.95	0.28	0	-0.72	-2.18	-1.29
OPM %	-	-	-791.67%	71.79%	-	-	-	-161.25%
Other Income	0	0	0	0	0	0	0	0
Interest	-1.07	-0.18	-0.18	-0.18	-0.33	-0.2	-0.11	0.02
Depreciation	0.01	0.1	0.11	-0.2	0	0.11	0.08	0.01
Profit Before Tax	-3.15	-2.93	-1.16	-0.13	0.13	-0.94	-2.31	-1.29
Tax %	-5.71%	134.13%	9.48%	0%	0%	0%	-0.87%	0%
Net Profit	-3.11	-2.83	-0.94	-0.19	0.23	-0.84	-2.26	-1.25
EPS	0	0	0	0	0	0	0	0

Profit & Loss

Consolidated Figures in Millions / View Standalone.

View:

Show growth under values

Years:

Unit:

Period (M)	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales	0	0	0	0.01	0.7	0.48	0.36	0.97	0.15	0.51
COGS	0	0	0	0.23	0.02	0.02	0.01	0.29	0.3	0
Gross Profit	0	-0	0	-0.22	0.68	0.46	0.35	0.68	-0.15	0.51
Gross Profit %	-	-	-	-2200%	97.14%	95.83%	97.22%	70.1%	-100%	100%
Operating Exp	0.04	11	4.14	2.56	4.14	8.97	12.06	15.8	6.62	5.21
EBITDA	-0.03	-11	-4.14	-5.92	-3.47	-10.37	-10.97	-15.2	-6.33	-4.34
Other Income	0	0	0	0	0	0	0	0	0	0
Interest	0	-0.01	-0.1	-0.46	-0.46	-0.33	-0.18	-0.11	-1.13	-0.74
Depreciation	0	0	-0.1	0.04	0.06	0.04	0.01	0.02	0.38	0.2
Profit Before Tax	-0.03	-11.01	-4.24	-6.43	-4.01	-10.81	-11.21	-15.51	-8.02	-5.37
Tax Rate %	6300%	0%	0%	5.75%	2%	2.04%	-7.4%	-5.16%	-3.24%	2.05%
Net Profit	-0.03	-11.01	-4.24	-5.58	-3.64	-9.79	-12.84	-16.42	-7.79	-4.9

Balance Sheet

Consolidated Figures in Millions / View Standalone.

View:

Show growth under values

Years:

Unit:

Period (M)
Cash & Bank
Investments
Fixed Assets
Current Assets
Other Assets
Total Assets
Equity Capital
Reserves
Borrowing/Debt
Current Liabilities
Other Liabilities
Total Liabilities & Equity

Cash Flow Statement

Consolidated Figures in Millions / View Standalone.

View:

Show growth under values

Years:

Unit:

Period (M)	Dec 2016	Dec 2017	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash Flow from Operating	-3.47	-1.6	-1.68	-0.63	-3.13	-4.56	-7.6	-7.4	-4.19	-1.81
Cash Flow from Investing	-0.16	-0.16	-7.49	-0.16	-0.04	-0.23	-0.81	-1.72	-0.36	0
Cash Flow from Financing	2.65	1.63	9.33	0.59	3.09	9.57	10	4.01	3.87	1.98
Net Cash Flow	0	0	0	0	0	0	0	0	0	0